Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions.
Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions.
复制标题
DOI：
10.3389/fonc.2020.562558
复制
发表时间：
2020
影响因子：
4.7
通讯作者：
DiNardo C
中科院分区：
文献类型：
--
作者：
Samra B;Konopleva M;Isidori A;Daver N;DiNardo C
过去十年见证了我们对分子生物学理解的重大进展，这带来了突破性的新疗法，其中重要的是 B 细胞淋巴瘤 2 (BCL-2) 抑制剂 Venetoclax。值得注意的是，对于因年龄或合并症而被认为“不适合”强化化疗的老年急性髓系白血病 (AML) 患者，基于 Venetoclax 的组合改善了预后，包括缓解率和总体生存率。这已转化为基于维奈托克的组合在学术和社区环境中的快速和广泛使用。其他基于维奈托克的组合正在针对 AML 进行研究，最终目标是提高许多亚组的治愈率；一线治疗和复发/难治性治疗，与移植后强化化疗相结合，或作为维持策略。在本文中，我们总结了基于维奈托克的组合的当前可用数据。我们还强调未满足医疗需求的领域，并为接受此类治疗的患者的管理提供实用的临床珍珠。
The past decade has witnessed major advances in our understanding of molecular biology, which led to breakthrough novel therapies, importantly including the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax. Notably, venetoclax-based combinations have improved outcomes, including both remission rates and overall survival, of older patients with acute myeloid leukemia (AML) deemed “unfit” for intensive chemotherapy due to age or comorbidities. This has translated into a rapid and widespread use of venetoclax-based combinations in both academic and community-based settings. Other venetoclax-based combinations are being investigated in AML with the ultimate goal of improving cure rates across many subgroups; frontline and relapsed/refractory, in combination with intensive chemotherapy, in the post-transplant setting, or as maintenance strategy. In this article, we summarize the current available data on venetoclax-based combinations. We also highlight areas of unmet medical need, and we offer practical clinical pearls for management of patients receiving such therapy.
登录
查看更多内容
影响因子：
11.4
作者：
通讯作者：
--
影响因子：
6.2
作者：
Burnett, Alan K.;Milligan, Donald;Wheatley, Keith
通讯作者：
Wheatley, Keith
影响因子：
158.5
作者：
DiNardo, C. D.;Stein, E. M.;Kantarjian, H. M.
通讯作者：
Kantarjian, H. M.
影响因子：
11.4
作者：
通讯作者：
--
影响因子：
16
作者：
Cheng, EHYA;Wei, MC;Korsmeyer, SJ
通讯作者：
Korsmeyer, SJ